Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF) (the “Company” or “Pure Global” or “PURE”), a vertically-integrated, growth-oriented life sciences cannabis company, is pleased to provide the following significant summary of updates to inform shareholders and stakeholders of activities and developments across the organization.
Flagship Canadian Facility – Brampton Campus
- Wholly owned subsidiary, PureSinse Inc. (“PureSinse”), licensed to grow under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is anticipating its ACMPR Sales License in the coming weeks
- PURE has successfully completed the Phase 1 build-out and commenced Phase 2 & Phase 3 congruent build-outs with completion expected Q4 2018 and Q1 2019 respectively
- Phase 2: 18,000 sq ft. proprietary multi-ponic vertical production with an expected funded production capacity of 4,000 kg per annum
- Phase 3: total 41,000 sq ft. proprietary multi-ponic vertical cultivation facility with an expected total funded production capacity of 8,000 kg per annum
- PureSinse has also fully secured inventory for product launch in time for October 17th legalization in Canada, and is securing additional product by pursuing and entering into long-term supply agreements. PURE expects revenue generation to commence immediately upon launch
- Initiated manufacturing and design of onsite Good Manufacturing Practice (“GMP”), along with advanced analytical R&D Laboratory for product formulation, derivatives and extracts processing
- Customer acquisition, branding, and sales strategy includes partnerships with major Canadian medical clinics, along with the expected inclusion into future provincial product calls nationwide
Flagship International Facility – Sativa Nativa S.A.S. – Colombia
- Signed binding LOI with Avicanna Inc. (“Avicanna”), as previously announced on August 15, 2018, to obtain a 60% interest in Sativa Nativa S.A.S. (“Sativa Nativa”) – with an option to increase the interest to 75%. Sativa Nativa is one of the few entities in Colombia currently licensed by the Colombian Ministry of Justice and Ministry of Health for: (1) the cultivation of psychoactive cannabis, (2) the cultivation of non-psychoactive cannabis, and (3) extraction of cannabis for the manufacture of cannabis derivatives
- Up to 28 hectares (69 acres) of agriculture land with irrigation and infrastructure at the foothills of the Sierra Nevada mountains, Santa Marta, Colombia
- 100,000 sq ft. greenhouse nearing construction completion, along with a 20,000 sq ft. GMP grade state-of-the-art greenhouse
- Expected production capacity of 15,000 kg per annum by Q2 2019
- Sativa Nativa has commenced design of an additional 1 million sq ft. greenhouse with expected production capacity of 150,000 kg per annum by 2020
- Upon completion of the above, Sativa Nativa will have a combined production capacity of 165,000 kg by Q1 2020
- Assuming 75% interest in Sativa Nativa, and the completion of the convertible debenture financing initiated by Pure Global, PURE will have total production capacity of 132,000 kg, in two countries by Q1 2020
- Total growing area for Pure Global is expected to be 904,000 sq ft. between the three 3 facilities
- The Company is evaluating additional high capacity growing methods to increase yield and optional organic standards
- Colombia provides ideal production climate with 12 hours of light year-round, allowing for 4 cycles per year at a fraction of the cost to build and operate facilities, compared to that in Canada – a significant leverage to produce low-cost inputs for value-added products destined for international export markets
- Avicanna Inc. partnership provides access to a comprehensive genetics program resulting in the registration of over 80 genetics and one of the largest characterized and registered genetic bank in Latin America
Malay Panchal, President & CEO of Pure Global stated: “The combined licenses give PURE two high value assets which will be production, processing, R&D, and distribution hubs. One hub is near the heart of Canada’s most populous regions including access to 20% of the nation’s population. The other hub is in an ideal climatic, industrial region for large scale commercial cannabis cultivation, manufacturing, and global distribution.”
Mr. Panchal added, “By securing the lowest input costs possible through the Colombian acquisition, these combined entities will be the foundation of PURE’s long-term sustainable and profitable growth plans, with goals of international distribution to every country with medical and future legal adult-use cannabis regulations.”
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) is a vertically-integrated, growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) focused on producing cannabis products for medical, wellness, health & beauty, natural health, and future legal adult use markets.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
CROP Infrastructure CEO, Michael Yorke, stated, “Greg can be considered one of the foremost authorities on the Jamaican cannabis industry. He will be of considerable assistance to CROP as the business develops there.
“Greg has the invaluable ability to effectively interact with stakeholders from both the private and public sectors and his knowledge of the industry, both in the Caribbean and North America, is truly extensive and that will be of great benefit to CROP as it expands even further internationally.”
Greg Douglas formally entered the Cannabis space in 2015 when he joined the Bureau of Standards Jamaica as their Management Information Systems (MIS) Manager. Shortly after joining the Bureau he was named as the Project Coordinator for a proposed Medical Cannabis (Ganja) Track and Trace Pilot Project.
Through this Greg was exposed to compliance mechanisms used in Colorado, touring state facilities which increased his understanding and appreciation of the industry while building relationships with Colorado’s compliance agency, along with local businesses.
Greg is now known internally at the Bureau as the ‘Ganja Man’ and externally by stakeholders as the ‘Bureau Man’. During April to November 2017 Greg was seconded to the Cannabis Licensing Authority (CLA) as their CEO. While there he became a part of history issuing the first commercial licenses.
He also sought to streamline internal processes to increase the efficiency of the Authority. He was part of the CLA team that visited Canada where the team met with both Canadian Government entities and officials (Health Canada, MP Bill Blair, Department of Finance), also with resident offices of the Jamaica Tourist Board and JAMPRO.
Greg resumed his duties at the Bureau of Standards in January 2018 and is engaged as a member of the team responsible for the creation of standards within the cannabis industry in Jamaica.
About CROP Infrastructure Corp.
CROP Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of assets includes cultivation properties in California, Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 16 Cannabis brands and has US and Italian distribution rights to a line of over 55 topical cannabis products from The Yield Growth Corp.
Disclaimer for Forward-Looking Information
Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected yield from The Jamaica Property; the technological effects of The Jamaica Property on production; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
MYM Nutraceuticals Inc. (CSE:MYM) is pleased to announce the appointment of Mr. Frank Klees to the Advisory Board of the Company. Mr. Frank Klees will serve as an advisor to the Company as part of the Company’s stated mission to pursue, build and develop all cannabis related opportunities in the province of Ontario.
Mr. Klees’s extensive experience and track record in government and the private sector makes him an ideal strategic advisor to the Company at this stage of its development. Mr. Klees served five terms as a Progressive Conservative Member of the Legislative Assembly of Ontario from 1995 to 2014. He served in various senior positions including Minister of Transportation, Minister of Tourism, Chief Government Whip, Deputy House Leader, Vice Chair of the Select Committee on the Proposed Transaction of the TMX Group and the London Stock Exchange Group. Over the course of 19 years as an elected politician, Mr. Klees established strong and trusted working relationships with all levels of government.
Mr. Klees has extensive business experience in the energy sector, financial services and real estate development. He was a co-founder and Executive Vice President of Municipal Gas Corporation, served as Corporate Director and Member of the Audit and Governance Committees of Universal Energy Ltd. and has been a member of the Supervisory Board of Rockwool North America since 2003. Mr. Klees is a Senior Advisor to numerous public and private enterprises and provides business development, government relations and strategic planning advisory services.
“We are excited to welcome Mr. Klees to the Company’s advisory board,” said Rob Gietl, CEO of MYM. “His decades of navigating the political landscape in Ontario will be of great value to MYM shareholders when it comes to doing business with the various levels of government in that province. In the coming years, the cannabis business in Canadawill be rife with competition, having Mr. Klees join us at this early stage will ensure that MYM will be competitive in Canada’s most populous province.”
Subject to compliance with all applicable laws and the rules of the Canadian Securities Exchange, MYM will grant to Klees 500,000 options to purchase MYM common shares. The Stock Options will have an exercise price of $1.25 and expire on August 17, 2020. They will vest as follows: 250,000 of the Stock Options will vest immediately with the remaining 250,000 Stock Options vesting quarterly beginning October 1, 2018.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that are anticipated to have over 1.5 million square feet of production space. MYM is also a shareholder in two additional cannabis production projects in Australia and Colombia. The “Northern Rivers Project” in New South Wales, Australia is expected to have 1.2 million square feet of cannabis production space. In Colombia, MYM partner, Colombia Organica, currently hold a seed to sale license for low THC cannabis and are in the licensing process for the cultivation and production of high THC cannabis extracts. Plans are underway for MYM and Colombia Organica to build a cannabis production facility in the region. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
Keep up to date with MYM on our social media channels:
SOURCE MYM Nutraceuticals Inc.
Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) today announced that the Company has elected to issue 5,657,957 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement with The Salzman Group previously announced on December 7, 2017 (the “December 2017 Agreement”) and the additional payments agreement announced on June 15, 2018 (the “June 2018 Agreement”). Under the December 2017 Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol (CBD) in the prevention of graft versus host disease (GVHD). Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.
The invoiced amounts to be paid in Common Shares to The Salzman Group is the amount of US$329,101 (or C$432,833.64 based on the daily average exchange rate for August 16, 2018 published by the Bank of Canada). The number of Common Shares to be issued is based on a deemed issue price of C$0.0765 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on August 16, 2018, the trading day prior to the Company’s election to pay the invoiced amounts in Common Shares. The Common Shares are expected to be issued to The Salzman Group today.
The Company and Salzman Group have also approved a modification to the irrevocable selling agreement established by The Salzman Group with its broker, such that the Common Shares issued today and any further Common Shares issued under the December 2017 Agreement and the June 2018 Agreement shall be sold on each of the ten trading days following deposit of such shares in the brokerage account of The Salzman Group (instead of being sold over three or five trading days).
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. (“Kalytera”) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (“GVHD”) .
Kalytera also intends to develop a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a versatile compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera will seek to develop innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavourable results. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third-parties, its securities, or financial or operating results (as applicable). Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera’s control. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
- Robert Farrell
Phivida [“fiii-vee-daa”] Holdings Inc (CSE:VIDA, OTCQX:PHVAF) announces that it has been awarded full DTC (Depository Trust Company) and CNS (Continuous-Net-Settlement) eligibility for its common shares that are listed for trading on the OTCQX® Best Market under the ticker symbol “PHVAF” in the United States.
The DTC manages the electronic clearing and settlement agency serving publicly traded companies in the USA. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process. CNS is an automated book-entry accounting system, which centralizes the settlement of security transactions and maintains an orderly flow of security and money balances between market participants.
DTC eligibility allows for cost-effective clearing and guaranteed settlement, simplifying and accelerating the receipt of stock and cash for investors. CNS eligibility ensures all DTC eligible trades and cash balances are centralized, cleared and settled in an orderly and efficient manner. CNS eligibility also means that, if purchasing shares in the Canadian market (CSE: VIDA), DTC will guarantee delivery to the United States, and trades of foreign issuer shares (OTCQX: PHVAF) will be settled in USD for added value and convenience for prospective US investors.
Graduation to the OTCQX market provides added; value, service and convenience to US based investors, brokers and institutions seeking to trade “PHVAF”. DTC and CNS eligibility simplifies and accelerates settlement and is expected to enhance liquidity of the Company’s common shares on the OTC marketplace.
About Phivida Holdings Inc.
Celebrating Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as in premium cannabinoid infused foods, beverages and clinical products. Using encapsulation technology, phytocannabinoids are converted into water soluble delivery format, enhancing bioavailability, solubility and timed release within the body. Phivida’s encapsulated cannabinoids are infused into functional beverages, foods and supplements with a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. The World Anti-Doping Association’s recent decision to lift its ban of CBD from hemp oil and the World Health Organization’s supports the clinical benefits of CBD worldwide. Phivida is traded on the Canadian Securities Exchange as “CSE: VIDA“, and on the OTCQX® Best Markets as “US: PHVAF“.
Naturally Splendid (TSXV:NSP) is pleased to announce that an additional Purchase Order of NATERA® branded products valued at approximately $100,000.00 CDN, has been received from their Australian distributor.
Naturally Splendid’s strategic alliance with our Australian distributor, a multi-divisional distribution company with eight wholly owned subsidiaries covering retail; food service; and practitioner markets, represents several thousand points of sales and is the foundation to launching multiple product lines in Australia.
The first shipment of NATERA® branded products cleared customs in Australia and arrived at our distributor’s warehouse in late 2017. The second shipment valued at approximately $140,000CDN, was shipped in a 40′ container for distribution throughout Australia. This most recent shipment is intended to expand the NATERA® consumer base and further penetrate the Australian market.
Naturally Splendid President Mr. Craig Goodwin states, “Our vertical integration strategy creates a unique position for the Company when measured against most other hemp companies. Since our first shipment to Australia, we have solidified our vertical integration to include our own hemp processing, expanded our bar manufacturing and test kitchen facility, applied for our Dealer License allowing for the extraction of CBD (cannabidiol) from hemp amongst many other activities, as well as have invested significant resources developing new products. Products developed by Naturally Splendid derived from industrial hemp for food, cosmetics, skincare, pet nutrition and care, will continue to find new markets such as Australia and we look forward to working with our distributors expanding the NATERA® brand there, thus creating an expanding opportunity to leverage our proprietary technologies like HempOmega™ and numerous other products that Naturally Splendid has developed as it relates to hemp.”
At the Australian Industrial Hemp Conference earlier this year, Mr. John Harvey, Managing Director AgriFutures Australia stated, “With the recent changes in the regulatory environment AgriFutures Australia has identified hemp as important emerging industry. Therefore, the Australian Industrial Hemp Conference comes at a particularly important time for the Australian industry to coordinate and to develop business models that will unlock the potential of this crop.”
Naturally Splendid CEO Mr. Douglas Mason states, “The position of AgriFutures Australia sends a positive signal in our opinion, for evolving hemp regulations including CBD (cannabidiol), derived in our case from hemp. Our previously announced Dealer License application as well as plans to build our own CBD extraction facility, further strengthens our opportunity in Australia and we look forward to expanding our product offerings there as regulations allow.”
About Naturally Splendid Enterprises Ltd.
Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and marijuana cannabinoid compounds in a broad spectrum of applications.
Naturally Splendid currently has four innovative divisions:
|(1)||BIOTECHNOLOGY – Focused on three major platforms:|
|• Proprietary HempOmega™ encapsulation|
|• Extraction and formulation with Cannabidiol (CBD)|
|• Hemp and plant-based proteins|
|NATERA® – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.|
|The Bar Makers (Prosnack Natural Foods Inc.) makers of (Elevate Me™) – lifestyle brand of healthy meal replacement products distributed throughout North America.|
|Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.|
|PawsitiveFX® – topical pet care products.|
|NATERA®CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.|
|NATERA®Skincare – brand of retail hemp based cosmeceutical products.|
|(3)||NATERA® Ingredients – bulk ingredients including HempOmega™|
|Naturally Splendid Hemp Processing is a science-based, industrial hemp seed processing business located in Abbotsford, BC. Listed as the only strictly organic hemp seed processor in North America.|
|(4)||Co-Packaging/Toll-Processing – packaging for house-brands (NATERA® and CHII) and third-party partners.|
For more information e-mail email@example.com or call Investor Relations at 604-673-9573
On Behalf of the Board of Directors
Mr. Douglas Mason
Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.